Blogs

Proton Pump Inhibitors MDL

Posted by Sarah Showard | Aug 03, 2017 | 0 Comments

Proton Pump Inhibitors (PPI) have officially been centralized in the District of New Jersey by the Judicial Panel on Multi-District Litigation (JPML) on the evening of August 2nd, 2017. More than (60) cases of the (161) constituent actions are already pending in the District of New Jersey. Judge Claire C. Cecchi will oversee Proton Pump Inhibitors MDL-2789.  This was the plaintiff's second motion to centralize after a denied request took place in January of 2017. The JPML reserves the right to grant additional motions to centralize under significant circumstances and that's exactly what they determined from a recent federal hearing in Los Angeles on August 3rd, 2017.

One of the key differences with this motion to centralize was having support from (2) of the primary defendants; AstraZeneca and Pfizer. Meanwhile, Proctor and Gamble "do not oppose centralization" while both Takeda and Novartis opposed centralization. It should be noted the panel opposed Takeda's request to be carved out of the MDL, considering there are a large number of "mixed use" cases filed with the potential to increase significantly.

Another point of contention is the fact each of these defendants are competitors and there are concerns over the protection of trade secrets, etc. The JPML addressed this concern by stating, "The transferee judge has wide discretion as to how the MDL should be defined". They continue to express the transferee judge may establish separate discovery, motion tracks and manage pretrial proceedings efficiently. This could be a non-issue as most of these medications no longer have patent protection.

For more information, including case acquisition, please call (480) 970-1180 to speak with a representative of Velawcity.

About the Author

Sarah Showard

Sarah Showard graduated from the University of Maryland in 1985, Magna Cum Laude with a Bachelor of Arts in English-Linguistics and a Certification in Women's Studies. She then graduated from New York University School of Law in 1988. Sarah began practice initially as an insurance defense attorney, and has been representing plaintiffs since 1990. Sarah has a son, Benjamin, who recently graduated from The Gregory School and will attend ASU in the fall, with future plans to attend law school and eventually join Showard Law Firm. In her spare time Sarah enjoys horseback riding and spending time in Sonoita with her husband Peter.

Comments

There are no comments for this post. Be the first and Add your Comment below.

Leave a Comment

Showard Law Firm-Tucson's Local Law Firm for defective drug & medical device claims.

Showard law firm group photo

Showard Law Firm is dedicated to compassionate representation for our clients who have been injured by defective products, dangerous drugs or the negligence of any individual or company. We are experienced in litigation and ready to ensure you receive the maximum possible settlement for your injuries, medical bills, mental anguish and other losses.

Showard Law Firm celebrates 10 years

10th anniversary showard

2016 marked the 10th anniversary of Showard Law Firm. After 18 years of practice, and a prior ten-year partnership, Sarah Showard and her longtime assistant, Maria De La Rosa, opened the doors of Showard Law Firm in October 2006. Sarah and everyone at Showard Law Firm is proud to serve Southern Arizona as the local law firm for defective drug and medical device claims and personal injury.